Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Democratic Party For the People Calls for Drug Pricing Overhaul
June 16, 2023
- First Generics for 11 APIs to Enter NHI Price List, Azilva Faces Most Contenders
June 15, 2023
- MSD’s Lyfnua Braces for Price Cuts under CEA Scheme
June 15, 2023
- Japan Diet Clears Lawmaker-Sponsored Dementia Bill
June 15, 2023
- MHLW Mulls New OTC Class to Bar Online Sales amid Unease over Morning After Pills
June 14, 2023
- LDP Policy Research Council Generally Approves Revised Honebuto Draft
June 14, 2023
- Label Revision Ordered for Opdivo, Yervoy to Add Meningitis Risks
June 14, 2023
- MHLW to Set Up Team Dedicated to Executing Healthcare DX Timeline
June 13, 2023
- 3 Japan Manufacturers of Plasma-Derived Products Call for Changes in Export Rules: PAFSC Committee
June 13, 2023
- Panelist Suggested Macroeconomic Indexing for Social Security Spending: CEFP Minutes
June 13, 2023
- MHLW Publishes Final Report by Expert Panel on Comprehensive Pharma Policy
June 13, 2023
- MHLW Panel OKs 170 More Health Damage Claims for COVID Vaccines
June 13, 2023
- Japan Diet Enacts Genomic Medicine Promotion Bill
June 12, 2023
- MHLW Calls for Switch from Noritren after Carcinogen Detection
June 12, 2023
- Honebuto Social Security Debate Culminates with LDP Push for Nixing Budget Cap
June 9, 2023
- Sumitomo to Urge Switch from Noritren over Carcinogen Risks, but Continues Shipments
June 8, 2023
- LDP Lawmakers Oppose Online Sale of Morning After Pills 3 Years after Switch
June 8, 2023
- LDP League Submits Proposal to Ensure Stable Generic Supplies
June 8, 2023
- Draft Honebuto Paper Unveiled, Cabinet OK Expected in Mid-June
June 8, 2023
- Expert Panel Broadly OKs Draft Report on Pharma Policies, Further Deliberations by Other Forums
June 7, 2023
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…